Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated at StockNews.com
StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a report published on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Nabriva Therapeutics Price Performance Nabriva Therapeutics has a 12 month low of $1.22 and a 12 month high of $8.45. The company has a market […]
StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a report published on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Nabriva Therapeutics Price Performance Nabriva Therapeutics has a 12 month low of $1.22 and a 12 month high of $8.45. The company has a market […]
